[Cryoprecipitate should have preference over factor VIII concentrate in the treatment of patients with hemophilia A]

MeSH terms

• Acquired Immunodeficiency Syndrome / transmission
• Costs and Cost Analysis
• Factor VIII / adverse effects
• Factor VIII / isolation & purification*
• Factor VIII / therapeutic use
• Hemophilia A / economics
• Hemophilia A / therapy*
• Humans
• Risk Factors